Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study

Table 3

Change from baseline in walking distance and patient-reported outcome measures in patients with postacute sequelae of SARS-CoV-2 after a modified enhanced external counterpulsation treatment.

Patient	Sex	Physical capacity, 6MWT	Psychological distress, HADS, two subscales		Health-related quality of life, RAND-36, eight subscales
		WD meters	Anxiety score	Depression score	PF score	RP score	BP score	GH score	VT score	SF score	RE score	MH score
1	F	−2.5	−4	−1	10	0	20	−19	−10	12	0	4
2	F	35	−3	0	0	0	0	0	10	37	0	0
3	M	9	0	1	−2	0	10	−15	5	0	0	0
4	F	16	0	1	0	25	−10	−5	5	0	−67	−12
5	F	−38	6	2	5	0	−33	10	−10	0	−100	−16
6	M	33	2	−1	−5	0	13	−1	5	0	0	0
7	M	19	4	−3	0	−50	2	0	30	0	0	12
8	M	23	−6	−6	35	100	10	30	45	25	0	20
9	F	27	0	−1	0	0	−23	−3	−15	12	−100	0
10	M	173.5	2	0	20	0	13	8	40	0	0	20
N = 10
Mean (SD)		29.5 (54.9)	0.1 (3.7)	−0.8 (2.3)	6.3 (12.4)	7.5 (37.4)	0.2 (17.2)	0.5 (13.7)	10.5 (21.1)	8.6 (13.1)	−26.7 (43.9)	2.8 (11.9)

6MWT, six-minute walk test; BP, bodily pain; F, female; GH, general health; HADS, hospital anxiety and depression scale; M, man; MH, mental health; PH, physical health; RE, role disability due to emotional health; RP, role disability due to physical health; SD, standard deviation; SF, social function; VT, vitality; WD, walking distance.